Drug Profile
GI 6207
Alternative Names: GI-6207; Recombinant Saccharomyces cerevisiae-CEA (610D)Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator GlobeImmune
- Developer GlobeImmune; ImmunityBio
- Class Cancer vaccines; Gene therapies; Immunotherapies; Yeasts
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Thyroid cancer
- Phase I/II Colorectal cancer; Pancreatic cancer; Triple negative breast cancer
Most Recent Events
- 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio
- 23 Feb 2021 Phase-I/II development for Triple negative Breast cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) is ongoing in USA (NCT03387085)
- 23 Feb 2021 Phase-I/II for Pancreatic cancer (Combination therapy, Second-line therapy or greater) is ongoing in USA (NCT03387098)